UnknownEarly Phase 1

Characterizing LAM With 11C-Choline PET/CT

China50 participantsStarted 2021-11

Plain-language summary

It was reported that TSC2-deficient cells enhance phosphatidylcholine synthesis via the Kennedy pathway. 11C-Choline can reflect the metabolic process of choline in vivo by intravenous injection. The purpose of this study is the ability of 11C-Choline PET/CT to evaluate the baseline condition of LAM patients and the efficacy of rapamycin after treatment.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- provide a written informed consent; Diagnostic CT or MRI suggesting a diagnosis of lymphangioleiomyomatosis. Exclusion Criteria: \- Females planning to bear a child recently or with childbearing potential; Known severe allergy or hypersensitivity to IV radiographic contrast； Inability to lie still for the entire imaging time.

What they're measuring

Standardized uptake value of 11C-Choline in LAM lesions

Timeframe: through study completion, an average of 2 year

Trial details

NCT IDNCT05087134

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-09

Contact for this trial

Guozhu Hou, MD

15611145656 15611145656@163.com

View on ClinicalTrials.gov More Lymphangioleiomyomatosis trials